ANNOUNCEMENT – Daruka Mahadevan, M.D., Ph.D., appointed Chief of the Division of Hematology and Medical Oncology
Afte r a comprehensive and multi-disciplinary national search, I am delighted to announce the appointment of Daruka Mahadevan, M.D., Ph.D., as chief of the Division of Hematology and Medical Oncology in the Department of Medicine, effective Dec. 1, 2019. Dr. Mahadevan will also lead the Hematology and Medical Oncology service line within the Mays Cancer Center. Dr. Mahadevan comes to us from the University of Arizona Cancer Center, an NCI-designated Comprehensive Cancer Center, where he serves as the director of the Early Phase Therapeutics Program and is the co-director of the Experimental Therapeutic Development Program. His recruitment will stimulate continued growth in our own Experimental and Developmental Therapeutics (EDT) Program and broaden our expertise in early phase therapeutic development.
Dr. Mahadevan received his Bachelor of Science in physiology and biochemistry with chemistry from the University of Reading, England, in 1982. He went on to the University of London to earn his doctorate in protein crystallography in 1986. He received his Bachelor of Medicine, Bachelor of Surgery (M.D. equivalent) from King’s College Hospital Medical School at the University of London in 1990. He completed his residency in internal medicine at the University of Connecticut Health Center in 1997, and his hematology oncology fellowship at the University of Arizona Health Sciences Center in 2002. Dr. Mahadevan is board certified by the American Board of Internal Medicine and the American Board of Medical Oncology.
Dr. Mahadevan’s major area of clinical interest is early phase therapeutics in the treatment and management of patients with pancreatic cancer, gastrointestinal stromal tumors, myelodysplastic syndromes and non-Hodgkin’s lymphoma, including chronic lymphocytic leukemia. He has a demonstrated track record of delivering first-in-human investigational agents for all oncology therapeutics and is a principal investigator or co-principal investigator on several National Institutes of Health and foundation grants. In addition, he has successfully directed a structure-based translational drug discovery laboratory program with the award of six U.S. patents for new drugs targeting novel driver oncogenes.
I want to especially thank Anand Karnad, M.D., for his exceptional leadership as the chief of the Division of Hematology and Medical Oncology. Dr. Karnad has provided crucial leadership during several challenging periods of time for the division and helped spur tremendous growth in volume and excellence in providing high-quality care to our patients. I appreciate Dr. Karnad for his inspirational patient-centered care, his deep compassion for his colleagues and his tireless commitment to the division. He will now be able to pursue his area of passion, the growth of the hematologic malignancy program and launch of stem cell transplantation and introduction of cellular-based therapies to the Mays Cancer Center.
Dr. Mahadevan was selected after an extensive national search led by a dedicated, multi-disciplinary team of UT Health San Antonio faculty, MD Anderson faculty and Myers Consulting. My sincere thanks to the members of the search committee for their hard work on this important recruitment.
Dr. Mahadevan and his wife of 18 years, Amy, have two daughters, Emily, 17, and Olivia, 14, who are in high school. Emily plays the baritone in the marching band and Olivia is in the lady’s silver choir.
Please join me in welcoming Daruka and Amy to the Mays Cancer Center family!
Ruben Mesa, M.D., FACP